LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: The Parathyroid Gland and Heart Disease.

Brown, Spandana J / Ruppe, Mary D / Tabatabai, Laila S

Methodist DeBakey cardiovascular journal

2017 Volume 13, Issue 2, Page(s) 49–54

Abstract: The parathyroid glands are critical to maintaining calcium homeostasis through actions of parathyroid hormone (PTH). Recent clinical and molecular research has shown that direct and indirect actions of PTH also affect the heart and vasculature through ... ...

Abstract	The parathyroid glands are critical to maintaining calcium homeostasis through actions of parathyroid hormone (PTH). Recent clinical and molecular research has shown that direct and indirect actions of PTH also affect the heart and vasculature through downstream actions of G protein-coupled receptors in the myocardium and endothelial cells. Patients with disorders of the parathyroid gland have higher incidences of hypertension, arrhythmias, left ventricular hypertrophy, heart failure, and calcific disease which translate into increased cardiac morbidity and mortality. Importantly, clinical research also suggests that early treatment of parathyroid disorders through medical or surgical management may reverse cardiovascular remodeling and mitigate cardiac risk factors.
Language	English
Publishing date	2017-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	2544079-2
ISSN	1947-6108 ; 1947-6094
ISSN (online)	1947-6108
ISSN	1947-6094
DOI	10.14797/mdcj-13-2-49
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Medications that affect calcium.

Ruppe, Mary D

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2008 Volume 17 Suppl 1, Page(s) 26–30

Abstract: ... parathyroid or 1,25-dihydroxyvitamin D-mediated regulation. Some medications are used specifically to alter ...

Abstract	Objective: To review medications that can affect serum calcium concentrations. Methods: The literature was reviewed for articles pertaining to medications that affect calcium concentrations. Results: The serum calcium concentration is tightly regulated because of the importance of this mineral in diffuse cellular processes. Many medications have been reported to cause changes in serum calcium levels by influencing intestinal calcium absorption, renal calcium resorption, and bone remodeling or through altering parathyroid or 1,25-dihydroxyvitamin D-mediated regulation. Some medications are used specifically to alter serum calcium as a therapeutic intervention. With others, the calcium disturbances are viewed as a side effect of the treatment. Conclusion: It is important to be aware of the influence that medications can have on serum calcium levels when evaluating patients with disorders of calcium homeostasis.
MeSH term(s)	Bicarbonates/adverse effects ; Bone Remodeling/drug effects ; Calcitonin/adverse effects ; Calcitriol/adverse effects ; Calcium/blood ; Estrogens/adverse effects ; Furosemide/adverse effects ; Humans ; Intestinal Absorption/drug effects ; Vitamin A/adverse effects
Chemical Substances	Bicarbonates ; Estrogens ; Vitamin A (11103-57-4) ; Furosemide (7LXU5N7ZO5) ; Calcitonin (9007-12-9) ; Calcitriol (FXC9231JVH) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2008-09-13
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1473503-9
ISSN	1934-2403 ; 1530-891X
ISSN (online)	1934-2403
ISSN	1530-891X
DOI	10.4158/EP10281.RA
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: FRACTURE LIAISON SERVICES: MULTIDISCIPLINARY APPROACHES TO SECONDARY FRACTURE PREVENTION.

Osuna, Patricia Mejia / Ruppe, Mary D / Tabatabai, Laila S

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2016 Volume 23, Issue 2, Page(s) 199–206

Abstract: Objective: A well-recognized gap exists between evidence-based recommendations for post-fracture care and actual clinical practice, demonstrated by the high percentage of fragility fracture patients who are neither diagnosed nor treated for osteoporosis. ...

Abstract	Objective: A well-recognized gap exists between evidence-based recommendations for post-fracture care and actual clinical practice, demonstrated by the high percentage of fragility fracture patients who are neither diagnosed nor treated for osteoporosis. Our purpose is to review fracture liaison service (FLS) models and to evaluate national and international experiences in secondary fracture prevention. Methods: We performed a systematic search of publication databases (MEDLINE, SCOPUS) and included randomized controlled trials, meta-analyses, and review articles using the following keywords: Fracture liaison services, Secondary prevention of fracture, Post-fracture healthcare gap, and fragility fractures. References were included from 2001-2015. We subsequently performed reference searches of retrieved articles and available literature was reviewed. Results: The efficacy of secondary fracture prevention programs correlates strongly with their intensity. Type A FLS Models are most successful in initiating diagnostic and treatment plans for fragility fracture patients. Adoption of FLS programs improves care by lowering mortality and refracture rates while also lowering healthcare costs. The quality of evidence supporting associations between FLS programs and improved outcomes was moderately strong due to the availability of longitudinal data from nationalized health systems. Conclusion: As our population ages and challenges to the healthcare system loom ever larger, it is imperative that we fund and champion fracture liaison services. The fracture liaison service has recently emerged as a novel clinical approach that uses coordinated, multidisciplinary care to improve post-fracture outcomes and reduce recurrent fractures. These programs are simple, targeted, high-yield and have the potential to protect our most vulnerable patients. Abbreviations: DXA = dual-energy x-ray absorptiometry FLS = fracture liaison service NCQA = National Committee of Quality Assurance NHS = National Health Service PCP = primary care physician PQRS = Physician Quality Reporting System QCDR = Qualified Clinical Data Registry.
MeSH term(s)	Aging ; Fractures, Bone/prevention & control ; Fractures, Bone/therapy ; Health Care Costs ; Humans ; Osteoporotic Fractures/epidemiology ; Referral and Consultation ; Secondary Prevention/methods
Language	English
Publishing date	2016-11-16
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Review
ZDB-ID	1473503-9
ISSN	1530-891X
ISSN	1530-891X
DOI	10.4158/EP161433.RA
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Vitamin D receptors and parathyroid glands.

Landry, Christine S / Ruppe, Mary D / Grubbs, Elizabeth G

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2008 Volume 17 Suppl 1, Page(s) 63–68

Abstract: Objective: To describe the function and metabolism of the vitamin D hormone and the role ... of the vitamin D receptor and the calcium-sensing receptor in the secretion of parathyroid hormone.: Methods ... A review of the literature was undertaken regarding the function and metabolism of vitamin D; the role of the vitamin D ...

Abstract	Objective: To describe the function and metabolism of the vitamin D hormone and the role of the vitamin D receptor and the calcium-sensing receptor in the secretion of parathyroid hormone. Methods: A review of the literature was undertaken regarding the function and metabolism of vitamin D; the role of the vitamin D receptor and calcium-sensing receptor in the secretion of parathyroid hormone; and the contemporary research regarding the interaction of vitamin D and parathyroid hormone in patients with vitamin D deficiency, primary hyperparathyroidism, and secondary hyperparathyroidism. Results: Over the last several years, great interest has been generated about the interaction of vitamin D and the parathyroid glands, gastrointestinal tract, kidney, and bone in relation to calcium and parathyroid hormone levels. Vitamin D has an important role in calcium and parathyroid hormone metabolism. Likewise, the vitamin D axis appears to be involved with the development of both primary and secondary hyperparathyroidism. The specific mechanism by which vitamin D interacts with the parathyroid gland to bring about observed effects is not yet fully understood. Conclusion: Future studies investigating the relationship of the vitamin D receptor, calcium-sensing receptor, and parathyroid glands are needed to enhance our knowledge of vitamin D deficiency and primary and secondary vitamin D deficiency.
MeSH term(s)	Humans ; Parathyroid Glands/metabolism ; Receptors, Calcitriol/metabolism ; Receptors, Calcium-Sensing/metabolism ; Vitamin D Deficiency/metabolism
Chemical Substances	Receptors, Calcitriol ; Receptors, Calcium-Sensing
Language	English
Publishing date	2008-09-13
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1473503-9
ISSN	1934-2403 ; 1530-891X
ISSN (online)	1934-2403
ISSN	1530-891X
DOI	10.4158/EP10325.RA
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Kaposi sarcoma in the setting of cushing disease.

Jeng, Leo / Rios, Adan / Ruppe, Mary D

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2008 Volume 17, Issue 4, Page(s) e87–91

Abstract: Objective: To report a case of a human immunodeficiency virus (HIV)-negative Kaposi sarcoma (KS) associated with Cushing disease (CD).: Methods: The details of case presentation, evaluation, diagnosis, and treatment are presented and cases of KS and ... ...

Abstract	Objective: To report a case of a human immunodeficiency virus (HIV)-negative Kaposi sarcoma (KS) associated with Cushing disease (CD). Methods: The details of case presentation, evaluation, diagnosis, and treatment are presented and cases of KS and CD published before November 1, 2010 on PubMed and Scopus are reviewed. Results: A 54-year-old Hispanic HIV-negative man presented with typical signs and symptoms of CD (easy bruisability, proximal muscle wasting, and abdominal fat pads). Numerous raised, purplish, nonblanching plaques 0.5 to 2 cm in diameter extended throughout his lower extremities. Biochemical tests and pituitary magnetic resonance imaging confirmed CD. A lesion biopsy showed atypical vascular proliferation positive by immunohistochemistry for human herpesvirus 8 (HHV-8), consistent with KS. He underwent 2 transsphenoidal surgeries followed by a bilateral adrenalectomy. After recovery, his KS was treated with a systemic combination of liposomal doxorubicin and paclitaxel. Conclusion: The occurrence of CD and KS is rare. Specific therapy for CD and chemotherapy for KS are effective in the treatment of KS associated with CD.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Doxorubicin/therapeutic use ; Herpesvirus 8, Human/pathogenicity ; Humans ; Male ; Middle Aged ; Paclitaxel/therapeutic use ; Pituitary ACTH Hypersecretion/diagnosis ; Pituitary ACTH Hypersecretion/virology ; Sarcoma, Kaposi/diagnosis ; Sarcoma, Kaposi/virology
Chemical Substances	Antineoplastic Agents ; Doxorubicin (80168379AG) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2008-09-13
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1473503-9
ISSN	1934-2403 ; 1530-891X
ISSN (online)	1934-2403
ISSN	1530-891X
DOI	10.4158/EP10355.CR
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.

Zhang, Xiaoping / Imel, Erik A / Ruppe, Mary D / Weber, Thomas J / Klausner, Mark A / Ito, Takahiro / Vergeire, Maria / Humphrey, Jeffrey / Glorieux, Francis H / Portale, Anthony A / Insogna, Karl / Carpenter, Thomas O / Peacock, Munro

Journal of clinical pharmacology

2016 Volume 56, Issue 2, Page(s) 176–185

Abstract: ... phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH]2 D) concentration ... from baseline in TmP per glomerular filtration rate, serum Pi, 1,25(OH)2 D, and bone markers for each dosing ...

Abstract	In X-linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH]2 D) concentration, with subsequent development of rickets or osteomalacia. KRN23 is a recombinant human IgG1 monoclonal antibody that binds to FGF23 and blocks its activity. Up to 4 doses of KRN23 were administered subcutaneously every 28 days to 28 adults with XLH. Mean ± standard deviation KRN23 doses administered were 0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg. The mean time to reach maximum serum KRN23 levels was 7.0 to 8.5 days. The mean KRN23 half-life was 16.4 days. The mean area under the concentration-time curve (AUCn ) for each dosing interval increased proportionally with increases in KRN23 dose. The mean intersubject variability in AUCn ranged from 30% to 37%. The area under the effect concentration-time curve (AUECn ) for change from baseline in TmP per glomerular filtration rate, serum Pi, 1,25(OH)2 D, and bone markers for each dosing interval increased linearly with increases in KRN23 AUCn . Linear correlation between serum KRN23 concentrations and increase in serum Pi support KRN23 dose adjustments based on predose serum Pi concentration.
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/pharmacology ; Area Under Curve ; Biomarkers ; Bone and Bones/metabolism ; Familial Hypophosphatemic Rickets/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Phosphorus/blood ; Young Adult
Chemical Substances	Antibodies, Monoclonal ; Biomarkers ; KRN23 monoclonal antibody ; Phosphorus (27YLU75U4W)
Language	English
Publishing date	2016-02
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	188980-1
ISSN	1552-4604 ; 0091-2700 ; 0021-9754
ISSN (online)	1552-4604
ISSN	0091-2700 ; 0021-9754
DOI	10.1002/jcph.570
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.176: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.

Ruppe, Mary D / Zhang, Xiaoping / Imel, Erik A / Weber, Thomas J / Klausner, Mark A / Ito, Takahiro / Vergeire, Maria / Humphrey, Jeffrey S / Glorieux, Francis H / Portale, Anthony A / Insogna, Karl / Peacock, Munro / Carpenter, Thomas O

Bone reports

2016 Volume 5, Page(s) 158–162

Abstract: X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 ...

Abstract	X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23). Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and the Western Ontario and McMaster Osteoarthritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23 antibody. Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutaneously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-escalation trial. Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these scales in the assessment of HRQoL in XLH. Both instruments indicated impairment of physical function at baseline with all mean scores showing a trend to improved health at study endpoint compared to baseline. When corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which measures the patient's perception of their own chronic functional impairments due to poor physical health remained significantly improved ( Conclusion: KRN23 administration was associated with significantly improved patient perception of their Physical Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are valid tools for assessing HRQoL in XLH.
Language	English
Publishing date	2016-05-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	2821774-3
ISSN	2352-1872
ISSN	2352-1872
DOI	10.1016/j.bonr.2016.05.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase.

Ruppe, Mary D / Huang, Stephen A / Jan de Beur, Suzanne M

Thyroid : official journal of the American Thyroid Association

2005 Volume 15, Issue 12, Page(s) 1369–1372

Abstract: Consumptive hypothyroidism is characterized by excessive inactivation of thyroid hormone by type 3 iodothyronine deiodinase (D3). Previously this rare syndrome was described in association with massive hemangiomas in children and in a single case of a ... ...

Abstract	Consumptive hypothyroidism is characterized by excessive inactivation of thyroid hormone by type 3 iodothyronine deiodinase (D3). Previously this rare syndrome was described in association with massive hemangiomas in children and in a single case of a hemangioendothelioma in an adult. Here we report the first case of consumptive hypothyroidism from a nonvascular tumor in a patient who required supraphysiologic doses of levothyroxine prior to the resection of a large malignant solitary fibrous tumor. The tumor expressed D3 message, protein and exhibited functional D3 enzymatic activity. The clinical presentation of this patient expands the differential diagnosis of hypothyroidism, adds to the growing list of paraneoplastic syndromes that impact the endocrine system, and extends the spectrum of tumor types associated with consumptive hypothyroidism.
MeSH term(s)	Humans ; Hypothyroidism/etiology ; Iodide Peroxidase/biosynthesis ; Male ; Middle Aged ; Paraneoplastic Syndromes/etiology ; Thyroid Neoplasms/enzymology
Chemical Substances	iodothyronine deiodinase type III (EC 1.11.1.-) ; Iodide Peroxidase (EC 1.11.1.8)
Language	English
Publishing date	2005-12
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1086044-7
ISSN	1557-9077 ; 1050-7256
ISSN (online)	1557-9077
ISSN	1050-7256
DOI	10.1089/thy.2005.15.1369
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3307: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 106: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.

Imel, Erik A / Zhang, Xiaoping / Ruppe, Mary D / Weber, Thomas J / Klausner, Mark A / Ito, Takahiro / Vergeire, Maria / Humphrey, Jeffrey S / Glorieux, Francis H / Portale, Anthony A / Insogna, Karl / Peacock, Munro / Carpenter, Thomas O

The Journal of clinical endocrinology and metabolism

2015 Volume 100, Issue 7, Page(s) 2565–2573

Abstract: ... and 1,25-dihydroxyvitamin D [1,25(OH)2D] were 1.6 ± 0.4 mg/dL, 1.9 ± 0.3 mg/dL, and 36.6 ± 14.3 pg/mL ...

Abstract	Context: In X-linked hypophosphatemia (XLH), elevated fibroblast growth factor 23 (FGF23) decreases the renal tubular maximum reabsorption rate of phosphate/glomerular filtration rate (TmP/GFR) and serum inorganic phosphorus (Pi), resulting in rickets and/or osteomalacia. Objective: The objective was to test the hypothesis that monthly KRN23 (anti-FGF23 antibody) would safely improve serum Pi in adults with XLH. Design: Two sequential open-label phase 1/2 studies were done. Setting: Six academic medical centers were used. Participants: Twenty-eight adults with XLH participated in a 4-month dose-escalation study (0.05-0.6 mg/kg); 22 entered a 12-month extension study (0.1-1 mg/kg). Intervention: KRN23 was injected sc every 28 days. Main outcome measure: The main outcome measure was the proportion of subjects attaining normal serum Pi and safety. Results: At baseline, mean TmP/GFR, serum Pi, and 1,25-dihydroxyvitamin D [1,25(OH)2D] were 1.6 ± 0.4 mg/dL, 1.9 ± 0.3 mg/dL, and 36.6 ± 14.3 pg/mL, respectively. During dose escalation, TmP/GFR, Pi, and 1,25(OH)2D increased, peaking at 7 days for TmP/GFR and Pi and at 3-7 days for 1,25(OH)2D, remaining above (TmP/GFR, Pi) or near [1,25(OH)2D] pre-dose levels at trough. After each of the four escalating doses, peak Pi was between 2.5 and 4.5 mg/dL in 14.8, 37.0, 74.1, and 88.5% of subjects, respectively. During the 12-month extension, peak Pi was in the normal range for 57.9-85.0% of subjects, and ≥25% maintained trough Pi levels within the normal range. Serum Pi did not exceed 4.5 mg/dL in any subject. Although 1,25(OH)2D levels increased transiently, mean serum and urinary calcium remained normal. KRN23 treatment increased biomarkers of skeletal turnover and had a favorable safety profile. Conclusions: Monthly KRN23 significantly increased serum Pi, TmP/GFR, and 1,25(OH)2D in all subjects. KRN23 has potential for effectively treating XLH.
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Familial Hypophosphatemic Rickets/blood ; Familial Hypophosphatemic Rickets/drug therapy ; Female ; Fibroblast Growth Factors/immunology ; Glomerular Filtration Rate/drug effects ; Humans ; Immunoglobulin G/administration & dosage ; Immunoglobulin G/adverse effects ; Male ; Middle Aged ; Phosphorus/blood ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/adverse effects ; Treatment Outcome ; Young Adult
Chemical Substances	Antibodies, Monoclonal ; Immunoglobulin G ; KRN23 monoclonal antibody ; Recombinant Proteins ; Phosphorus (27YLU75U4W) ; Fibroblast Growth Factors (62031-54-3) ; fibroblast growth factor 23 (7Q7P4S7RRE)
Language	English
Publishing date	2015-04-28
Publishing country	United States
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	3029-6
ISSN	1945-7197 ; 0021-972X
ISSN (online)	1945-7197
ISSN	0021-972X
DOI	10.1210/jc.2015-1551
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

2018 Volume 33, Issue 8, Page(s) 1383–1393

Abstract: In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present ... ...

Abstract	In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1 mg/kg (n = 68) or placebo (n = 66) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p < 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean ± standard error [SE] difference, -8.1 ± 3.24; p = 0.012). Reductions in WOMAC physical function subscale (-4.9 ± 2.48; p = 0.048) and Brief Pain Inventory worst pain (-0.5 ± 0.28; p = 0.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p < 0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.
MeSH term(s)	Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Biomarkers/metabolism ; Bone Remodeling/drug effects ; Calcium/metabolism ; Double-Blind Method ; Familial Hypophosphatemic Rickets/drug therapy ; Familial Hypophosphatemic Rickets/physiopathology ; Female ; Fibroblast Growth Factors/antagonists & inhibitors ; Fibroblast Growth Factors/immunology ; Homeostasis ; Humans ; Male ; Placebos ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal ; Biomarkers ; Placebos ; Fibroblast Growth Factors (62031-54-3) ; fibroblast growth factor 23 (7Q7P4S7RRE) ; burosumab (G9WJT6RD29) ; Calcium (SY7Q814VUP)
Language	English
Publishing date	2018-06-26
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	632783-7
ISSN	1523-4681 ; 0884-0431
ISSN (online)	1523-4681
ISSN	0884-0431
DOI	10.1002/jbmr.3475
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito